Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 3/20 | 0.41 |
| ▸ | RXRB | P28702 | 3/20 | 0.41 |
| ▸ | RXRG | P48443 | 3/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10670296 | 0.85 | MAPK14 (0.49) | PTGER1SRD5A2SRD5A1FOLH1MAPK14 | |
| SCHEMBL12949558 | 0.83 | MRGPRX4 (0.41) | MRGPRX4PTGER1SRD5A2SRD5A1FOLH1 | |
| SCHEMBL12949645 | 0.82 | MAPK14 (0.43) | PTGER1MAPK14MEN1KMT2A | |
| SCHEMBL29067974 | 0.81 | SRD5A2 (0.47) | MRGPRX4PTGER1SRD5A2SRD5A1FOLH1 | |
| SCHEMBL9662923 | 0.80 | SRD5A2 (0.47) | MRGPRX4PTGER1SRD5A2SRD5A1FOLH1 | |
| SCHEMBL13555543 | 0.79 | MAPK14 (0.38) | MRGPRX4MAPK14 | |
| SCHEMBL2115801 | 0.78 | SRD5A2 (0.51) | MRGPRX4RXRARXRBRXRGPTGER1 | |
| SCHEMBL14124908 | 0.77 | FOLH1 (0.46) | RXRARXRBRXRGPTGER1SRD5A2 | |
| SCHEMBL10668010 | 0.76 | MAPK14 (0.48) | PTGER1MAPK14NOTUMMEN1KMT2A | |
| SCHEMBL12949898 | 0.73 | MAPK14 (0.41) | RXRARXRBRXRGMAPK14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-9938240-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX INC. (CA) | 2018-04-10 | — | — | US | disclosed |
| US-20170247329-A1 | \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ | APOTEX TECHNOLOGIES INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170247329-A1 | \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ | APOTEX TECHNOLOGIES INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | THE BANK OF NOVA SCOTIA (CA) | 2017-03-30 | — | — | US | disclosed |
| US-9550733-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2017-01-24 | — | — | US | disclosed |
| US-9550733-B2 | Fluorinated derivatives of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2017-01-24 | — | — | US | disclosed |
| US-20160083346-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | APOTEX TECHNOLOGIES INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20160083346-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | APOTEX TECHNOLOGIES INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20150274665-A1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | FLORIDA TURBINE TECHNOLOGIES, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9073865-B2 | Fluorinated derivates of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2015-07-07 | — | — | US | disclosed |
| US-9073865-B2 | Fluorinated derivates of 3-hydroxypyridin-4-ones | APOTEX TECHNOLOGIES INC. (CA) | 2015-07-07 | — | — | US | disclosed |
| EP-2448922-B1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC (CA) | 2014-08-20 | — | — | EP | disclosed |
| EP-2448922-B1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-20120270882-A1 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270882-A1 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| EP-2448922-A1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | Apotex Technologies Inc. (CA) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011000104-A1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011000104-A1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083346-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | FH, FECH, FPGS | MRGPRX4 3471/4885RXRA 2502/4885RXRB 2703/4885 |
| US-20120270882-A1 | FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES | FH, FECH, FTH1 | MRGPRX4 2638/4885RXRA 3344/4885RXRB 3568/4885 |
| US-20170088518-A1 | Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones | FH, FECH, FPGS | MRGPRX4 3409/4885RXRA 2605/4885RXRB 2788/4885 |
| US-20170247329-A1 | \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ | FH, FECH, FPGS | MRGPRX4 3747/4885RXRA 2935/4885RXRB 3108/4885 |
| US-20150274665-A1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | FH, FECH, TFRC | MRGPRX4 2287/4885RXRA 3108/4885RXRB 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.